From Financialpost · · 1m 20s
entyvio achieves disease clearance in ulcerative colitis trial
entyvio treatment targets disease clearance in ulcerative colitis, reducing complications by 70%.
In brief
entyvio treatment targets disease clearance in ulcerative colitis, reducing complications by 70%. entyvio vedolizumab prolongs time to ulcerative colitis complications by 70% when achieving disease clearance versus symptomatic remission. Originally reported by Financialpost.
verdict trial results
verdict trial shows treating ulcerative colitis to disease clearance reduces complications by 70% compared to symptomatic remission.
“verdict is the first trial to provide macroscopic and microscopic evidence of intestinal tissue repair associated with disease clearance in largely bio-naïve patients treated with an advanced therapy”
disease clearance definition
disease clearance combines corticosteroid-free symptomatic, endoscopic and histologic remission for deeper healing.
“disease clearance is a treatment target that combines three levels of remission: corticosteroid-free symptomatic remission, endoscopic remission, and histologic remission”
trial design
verdict randomized patients to three treatment targets: symptomatic remission, symptomatic plus endoscopic remission, or disease clearance.
“verdict randomized adults with moderate to severe ulcerative colitis to three increasingly stringent csf treatment targets”
key findings
57% of patients achieved disease clearance by week 16, reducing uc complications by 70% over 80 weeks.
“treating to stringent composite targets with entyvio reduced uc complication risk by ~70%, up to 80 weeks after target achievement”
gut healing evidence
molecular analysis shows inflammation pathways improved in patients achieving disease clearance by week 16.
“proteomic and transcriptomic analyses identified distinct molecular patterns among bio-naïve patients who achieved disease clearance by week 16”
complication rates
51 uc-related complications occurred, with rescue therapy being the most frequent complication.
“51 uc-related complications occurred, with use of rescue therapy being the most frequent”
safety profile
adverse events were similar across groups with no new safety signals identified.
“the safety profile observed throughout 96 weeks was generally consistent with previously reported data, with no new safety signals identified”
takeda's perspective
takeda emphasizes entyvio's ability to achieve gut healing without corticosteroids in bio-naïve patients.
“for people living with uc, symptom relief does not always tell the full story of what is happening beneath the surface”
clinical significance
disease clearance targets may reduce long-term uc complications and improve quality of life.
“the impact of ulcerative colitis can extend well beyond day-to-day symptoms”
next steps
further research needed to understand molecular changes in disease clearance and long-term outcomes.
“these exploratory findings may contribute to a better understanding of the biology associated with disease clearance”
The short version
entyvio vedolizumab prolongs time to ulcerative colitis complications by 70% when achieving disease clearance versus symptomatic remission.
